Tissue-type Plasminogen Activator Requires a Co-receptor to Enhance NMDA Receptor Function

Overview

Journal J Neurochem

Specialties Chemistry
Neurology

Date 2008 Sep 18

PMID 18796005

Citations 58

Authors

Andre L Samson

Simon T Nevin

David Croucher

Beeri Niego

Philip B Daniel

Thomas W Weiss

Eliza Moreno

Denis Monard

Daniel A Lawrence

Robert L Medcalf

Affiliations

Soon will be listed here.

Abstract

Glutamate is the main excitatory neurotransmitter of the CNS. Tissue-type plasminogen activator (tPA) is recognized as a modulator of glutamatergic neurotransmission. This attribute is exemplified by its ability to potentiate calcium signaling following activation of the glutamate-binding NMDA receptor (NMDAR). It has been hypothesized that tPA can directly cleave the NR1 subunit of the NMDAR and thereby potentiate NMDA-induced calcium influx. In contrast, here we show that this increase in NMDAR signaling requires tPA to be proteolytically active, but does not involve cleavage of the NR1 subunit or plasminogen. Rather, we demonstrate that enhancement of NMDAR function by tPA is mediated by a member of the low-density lipoprotein receptor (LDLR) family. Hence, this study proposes a novel functional relationship between tPA, the NMDAR, a LDLR and an unknown substrate which we suspect to be a serpin. Interestingly, whilst tPA alone failed to cleave NR1, cell-surface NMDARs did serve as an efficient and discrete proteolytic target for plasmin. Hence, plasmin and tPA can affect the NMDAR via distinct avenues. Altogether, we find that plasmin directly proteolyses the NMDAR whilst tPA functions as an indirect modulator of NMDA-induced events via LDLR engagement.

Citing Articles

Modeling and correction of protein conformational disease in iPSC-derived neurons through personalized base editing.

Konishi C, Mulaiese N, Butola T, Zhang Q, Kagan D, Yang Q Mol Ther Nucleic Acids. 2025; 36(1):102441.

PMID: 39877004 PMC: 11773622. DOI: 10.1016/j.omtn.2024.102441.

Intracellular tPA-PAI-1 interaction determines VLDL assembly in hepatocytes.

Dai W, Zhang H, Lund H, Zhang Z, Castleberry M, Rodriguez M Science. 2023; 381(6661):eadh5207.

PMID: 37651538 PMC: 10697821. DOI: 10.1126/science.adh5207.

Low-density lipoprotein receptor-related protein-1 (LRP1) in the glial lineage modulates neuronal excitability.

Faissner A Front Netw Physiol. 2023; 3:1190240.

PMID: 37383546 PMC: 10293750. DOI: 10.3389/fnetp.2023.1190240.

An antibody that targets cell-surface glucose-regulated protein-78 inhibits expression of inflammatory cytokines and plasminogen activator inhibitors by macrophages.

Gunner C, Azmoon P, Mantuano E, Das L, Zampieri C, Pizzo S J Cell Biochem. 2023; 124(5):743-752.

PMID: 36947703 PMC: 10200756. DOI: 10.1002/jcb.30401.

Blood tissue Plasminogen Activator (tPA) of liver origin contributes to neurovascular coupling involving brain endothelial N-Methyl-D-Aspartate (NMDA) receptors.

Furon J, Yetim M, Pouettre E, Martinez de Lizarrondo S, Maubert E, Hommet Y Fluids Barriers CNS. 2023; 20(1):11.

PMID: 36737775 PMC: 9896721. DOI: 10.1186/s12987-023-00411-w.

References

Su E, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J . Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med. 2008; 14(7):731-7. PMC: 2811427. DOI: 10.1038/nm1787. View

Weiss T, Samson A, Niego B, Daniel P, Medcalf R . Oncostatin M is a neuroprotective cytokine that inhibits excitotoxic injury in vitro and in vivo. FASEB J. 2006; 20(13):2369-71. DOI: 10.1096/fj.06-5850fje. View

Martin A, Kuhlmann C, Trossbach S, Jaeger S, Waldron E, Roebroek A . The functional role of the second NPXY motif of the LRP1 beta-chain in tissue-type plasminogen activator-mediated activation of N-methyl-D-aspartate receptors. J Biol Chem. 2008; 283(18):12004-13. DOI: 10.1074/jbc.M707607200. View

Gosalia D, Salisbury C, Maly D, Ellman J, Diamond S . Profiling serine protease substrate specificity with solution phase fluorogenic peptide microarrays. Proteomics. 2005; 5(5):1292-8. DOI: 10.1002/pmic.200401011. View

Qiu Z, Strickland D, Hyman B, Rebeck G . alpha 2-Macroglobulin exposure reduces calcium responses to N-methyl-D-aspartate via low density lipoprotein receptor-related protein in cultured hippocampal neurons. J Biol Chem. 2002; 277(17):14458-66. DOI: 10.1074/jbc.M112066200. View

Kumada M, Niwa M, Hara A, Matsuno H, Mori H, Ueshima S . Tissue type plasminogen activator facilitates NMDA-receptor-mediated retinal apoptosis through an independent fibrinolytic cascade. Invest Ophthalmol Vis Sci. 2005; 46(4):1504-7. DOI: 10.1167/iovs.04-0595. View

. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333(24):1581-7. DOI: 10.1056/NEJM199512143332401. View

Kvajo M, Albrecht H, Meins M, Hengst U, Troncoso E, Lefort S . Regulation of brain proteolytic activity is necessary for the in vivo function of NMDA receptors. J Neurosci. 2004; 24(43):9734-43. PMC: 6730139. DOI: 10.1523/JNEUROSCI.3306-04.2004. View

Benchenane K, Castel H, Boulouard M, Bluthe R, Fernandez-Monreal M, Roussel B . Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory. J Cell Sci. 2007; 120(Pt 4):578-85. DOI: 10.1242/jcs.03354. View

10.

Xia H, Hornby Z, Malenka R . An ER retention signal explains differences in surface expression of NMDA and AMPA receptor subunits. Neuropharmacology. 2001; 41(6):714-23. DOI: 10.1016/s0028-3908(01)00103-4. View

11.

Norris E, Strickland S . Modulation of NR2B-regulated contextual fear in the hippocampus by the tissue plasminogen activator system. Proc Natl Acad Sci U S A. 2007; 104(33):13473-8. PMC: 1948906. DOI: 10.1073/pnas.0705848104. View

12.

Pawlak R, Rao B, Melchor J, Chattarji S, McEwen B, Strickland S . Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus. Proc Natl Acad Sci U S A. 2005; 102(50):18201-6. PMC: 1312427. DOI: 10.1073/pnas.0509232102. View

13.

Boucher P, Gotthardt M, Li W, Anderson R, Herz J . LRP: role in vascular wall integrity and protection from atherosclerosis. Science. 2003; 300(5617):329-32. DOI: 10.1126/science.1082095. View

14.

Wang Y, Tsirka S, Strickland S, Stieg P, Soriano S, Lipton S . Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med. 1998; 4(2):228-31. DOI: 10.1038/nm0298-228. View

15.

Fernandez-Monreal M, Lopez-Atalaya J, Benchenane K, Leveille F, Cacquevel M, Plawinski L . Is tissue-type plasminogen activator a neuromodulator?. Mol Cell Neurosci. 2004; 25(4):594-601. DOI: 10.1016/j.mcn.2003.11.002. View

16.

Yepes M, Sandkvist M, Coleman T, Moore E, Wu J, Mitola D . Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J Clin Invest. 2002; 109(12):1571-8. PMC: 151009. DOI: 10.1172/JCI14308. View

17.

Kloda A, Adams D . Voltage-dependent inhibition of recombinant NMDA receptor-mediated currents by 5-hydroxytryptamine. Br J Pharmacol. 2005; 144(3):323-30. PMC: 1576009. DOI: 10.1038/sj.bjp.0706049. View

18.

Matys T, Strickland S . Tissue plasminogen activator and NMDA receptor cleavage. Nat Med. 2003; 9(4):371-2; author reply 372-3. DOI: 10.1038/nm0403-371. View

19.

Horn I, van den Berg B, van der Meijden P, Pannekoek H, van Zonneveld A . Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein. Evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding. J Biol Chem. 1997; 272(21):13608-13. DOI: 10.1074/jbc.272.21.13608. View

20.

Pawlak R, Melchor J, Matys T, Skrzypiec A, Strickland S . Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci U S A. 2005; 102(2):443-8. PMC: 544297. DOI: 10.1073/pnas.0406454102. View